ALEXANDRIA, Va., April 15 -- United States Patent no. 12,600,965, issued on April 14, was assigned to Alnylam Pharmaceuticals Inc. (Cambridge, Mass.).
"Modified double stranded oligonucleotide" was invented by Donald Foster (Cambridge, Mass.), Mark K. Schlegel (Cambridge, Mass.) and Christopher Brown (Cambridge, Mass.).
According to the abstract* released by the U.S. Patent & Trademark Office: "One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these d...